35 results about "Vertebrate" patented technology

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

The invention provides a method of monitoring blood flow in a vertebrate animal subject. Unfocussed plane-wave ultrasound pulses are transmitted into the subject, along a transmission axis, from a single-element ultrasound transducer (2) fastened to the subject (5). Reflections of the ultrasound pulses are received, generating a succession of pulse-Doppler response signals over time. Each pulse-Doppler response signal is processed to determine a first respective spatial-maximum velocity value for blood flowing towards the single transducer element (2), and a second respective spatial-maximum velocity value for blood flowing away. Heartbeats are identified from said spatial-maximum velocity values and a quality metric is assigned to each identified heartbeat. A subset of the spatial-maximum velocity values is identified for which the assigned quality metric exceeds a threshold level. The values from the subset are monitored, and, when a set of values from the subset satisfies a predetermined alert criterion an audible or visual alert is signalled.

A method of stimulating dentin generation includes applying a polymerizable composition to exposed dental pulp in a dentate mammal or a dentate non-mammalian vertebrate; wherein the polymerizable composition comprises a hydroxy-substituted azobenzene group having the structurewherein x, R1, R2, R4, R5, R6, R7, R8, R9, and R10 are defined herein; and polymerizing the polymerizable composition; wherein the amount of the hydroxy-substituted azobenzene group applied to the exposed dental pulp is effective to promote dentin generation.

Provided is an approach which can express and function a G protein-coupled receptor (GPCR). The present invention provides a method for expressing a GPCR polypeptide, comprising expressing in a cell a GPCR polypeptide consisting of an amino acid sequence obtained by, in an amino acid sequence of a GPCR of interest (provided that an olfactory receptor is excluded), altering at least one amino acid residue different from that in a consensus amino acid sequence to an amino acid residue at a position corresponding thereto in the consensus amino acid sequence, wherein the consensus amino acid sequence is an amino acid sequence derived by alignment of the amino acid sequence of the GPCR of interest and amino acid sequences of GPCRs encoded by orthologs of the GPCR of interest in vertebrates.

The invention belongs to the technical field of pest control, and discloses application of a nitrogen-containing heterocyclic compound in control of ampullaria gigas. According to the invention, a nitrogen-containing heterocyclic compound with the activity of killing ampullaria gigas is screened by taking ampullaria gigas arginine kinase as an action target, and the nitrogen-containing heterocyclic compound is N-[4-(3, 5-diphenyl-4, 5-dihydro-1H-pyrazole-1-yl) benzyl]-N-(1-hexyl-1H-benzimidazole-2-yl) amine. The nitrogen-containing heterocyclic compound is used as an active component to be prepared into a suspending agent or a granule, the suspending agent or the granule has an excellent killing effect on ampullaria gigas, and compared with an existing arginine kinase inhibitor quercetin, the nitrogen-containing heterocyclic compound is higher in activity, good in selectivity, low in toxicity to vertebrates and huge in application potential.

The invention discloses a preparation method and application of a quail CENP-A polyclonal antibody, and the preparation method of the quail CENP-A polyclonal antibody comprises the following steps: constructing a recombinant expression vector containing a CENP-A target gene segment as shown in SEQ ID NO.1; transforming the recombinant expression vector into a competent cell, inducing expression of a fusion protein, collecting and purifying to obtain a CENP-A recombinant protein; carrying out animal immune treatment by taking the CENP-A recombinant protein as an antigen, and collecting and separating an antibody in animal serum as a CENP-A polyclonal antibody. The invention also develops a method and a device for CUAMP; the quail CENP-A antibody sequenced by Tag fills up the blank of a quail commercial CENP-A antibody, is also an important basic work for further constructing a quail genome complete map, and provides a basic support for subsequently revealing how centromere related genes of vertebrates such as birds evolve among different species.

The present invention relates to the field of genome-editing, more specific of difficult to transform organisms such as e.g. invertebrates and in particular Arthropoda. The present disclosure provides a combination comprising one or more cationic nanoparticles, one or more endosomal escape reagent(s), and one or more ribonucleoprotein (RNP) complexes wherein said RNP comprises a Cas RNA-guided nuclease associated with a guide RNA (gRNA), and the use thereof in the production of a non-human genetically modified organism. The invention further provides a combination as defined herein for use in CRISPR based methods.

The invention discloses a method for efficiently extracting genome DNA (Deoxyribose Nucleic Acid) of ophiurocephalus serratus. The method comprises the following steps: mixing a sample with a lysis solution and metal balls, crushing the mixture at-20 to-10 DEG C for 250-350s at 40-60Hz, and placing the crushed sample at-20 to 4 DEG C; cracking the sample at the temperature of 50-60 DEG C for 4-6 minutes; centrifuging at 2-4 DEG C, taking a supernatant, adding an extraction agent, and uniformly mixing; centrifuging at 2-4 DEG C, taking an upper-layer solution, adding an extracting agent, and uniformly mixing; centrifuging at 2-4 DEG C, taking an upper-layer solution, adding isopropanol, uniformly mixing, and standing at-20--15 DEG C for 20-30 minutes; centrifuging at 2-4 DEG C, discarding the supernatant, washing the precipitate with an ethanol solution, and dissolving with an eluent; the lysis solution contains CTAB (Cetyltrimethyl Ammonium Bromide), protease K and beta-mercaptoethanol. According to the invention, the problem of high-mineralization echinodermis sample treatment is solved, and a high-quality nucleic acid template and a new technology are provided for research on ocean invertebrate genetics.

The present invention relates to improved LAMP constructs comprising cancer antigens. Specifically, improved LAMP constructs comprising specific fragments of LAMP endodomain are provided to deliver cancer antigens to immune cells for enhanced processing. These LAMP constructs are useful in the treatment of diseases, in particular hyperproliferative disorders and / or cancer. The improved LAMP constructs, when administered to a subject, allow presentation of a correctly configured three-dimensional epitope for generating an immune response. The improved LAMP constructs may be multivalent molecules, and / or may be provided as part of multivalent vaccines containing two or more LAMP constructs. The improved LAMP constructs described herein can also be used to produce antibodies when administered to non-human vertebrates.

The present invention discloses a method for increasing the yield of European oyster lysozyme, and belongs to the field of bioengineering. The present invention screens and obtains European oyster-derived lysozyme with relatively high enzyme activity from 12 different sources of lysozyme gene sequences from vertebrates, mollusks, poultry and insects, and realizes the active expression of the enzyme in Pichia pastoris. The present invention also fuses short peptides and protein tags of different amino acids to the N-terminus of OElyz. When the Sumo tag is fused, the extracellular enzyme activity of recombinant OElyz reaches 382.6U / mL at the shake flask level, and this yield level can meet the application requirements of lysozyme in the fields of medicine, biotechnology and food.

The present invention relates to the field of genome-editing, more specific of difficult to transform organisms such as e.g. invertebrates and in particular Arthropoda. The present disclosure provides a combination comprising one or more cationic nanoparticles, one or more endosomal escape reagent(s), and one or more ribonucleoprotein (RNP) complexes wherein said RNP comprises a Cas RNA-guided nuclease associated with a guide RNA (gRNA), and the use thereof in the production of a non-human genetically modified organism. The invention further provides a combination as defined herein for use in CRISPR based methods.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

Provided are a modified RNA demethylase, a nucleic acid encoding the modified RNA demethylase, the use thereof, a plant cultivation method, and a product. Compared with an original RNA demethylase derived from algae or invertebrates, the modified RNA demethylase is obtained by means of adding a specific peptide fragment sequence at the N-terminus or C-terminus of the original RNA demethylase. The modified RNA demethylase or the nucleic acid encoding the modified RNA demethylase is introduced into an initial plant to obtain a target plant having optimized traits compared with the initial plant.

Pharmaceutical formulations are described for use in viscosupplementation, comprising artificial peptides characterized by a proline sequence prevalent in key matricellular proteins that partake in wound healing as well as in bone and cartilage formation and connective tissue maintenance in all vertebrates. The current invention relates to a pharmaceutical formulation in the form of a gel comprising a. an artificial peptide comprising the amino acid sequence of Pro-X-X-Pro-Y-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Y-Y-Y-Pro-Y-Y-Y-Y-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Pro-Y-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Y-Pro-X-X- Pro-Y-Y-Pro-X-X-Pro-Y-Y- Pro-X-X-Pro-Y-Pro-Pro-X-Pro-Pro-X-X-X-X-X-X-X-X-Pro-X-X-Pro-X-X-X-X (SEQ ID NO 1 ) and / or an artificial peptide comprising or consisting of the amino acid sequence of Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y- Pro-X-X-Pro-Y-Y- Pro-Y-Pro-Pro-X-Pro-Pro (SEQ ID NO 2), wherein i) Pro is proline; ii) X is an amino acid selected from the group consisting of Ala, lie, Leu, Met, Phe, Trp and Vai; iii) Y is an amino acid selected from the group consisting of Asn, Cys, Gin, Ser, Thr and Tyr, b. cross-linked Hyaluronicfibres (HA-XL), and c. linear hyaluronic acid fibres (HA), for use in viscosupplementation.

The invention relates to the technical field of biological tissue engineering scaffolds, in particular to a whole intervertebral disc decellularized tissue engineering scaffold as well as a preparation method and application thereof. The method comprises the following steps: taking an intervertebral disc-bone complex of a vertebrate as a sample, and sequentially carrying out surface polishing treatment, degreasing treatment and cryopreservation rewarming treatment on the sample to obtain a pretreated sample; placing the pretreated sample in a Tris-HCl buffer solution containing a surfactant and a protease inhibitor, and carrying out oscillation treatment; putting the sample subjected to oscillation treatment into a decellularization solution, and carrying out decellularization treatment; putting the sample subjected to the decellularization treatment into a nuclease buffer solution, and carrying out nuclease treatment; and sequentially washing and freeze-drying the nuclease treated sample to obtain the whole intervertebral disc decellularized tissue engineering scaffold. Most of cell components and genetic materials are removed from the scaffold, a relatively complete extracellular matrix structure and mechanical properties are reserved, and the scaffold can be applied to the field of intervertebral disc repair and regenerative medicine.

Provided are a one-step extraction kit, an extraction method, and a high-throughput sequencing method for vertebrate mitochondrial genomic DNA and the use thereof. The kit comprises: a reagent A comprising 3.25-4.75M guanidinium isothiocyanate, 0.65-0.85M sodium citrate, and 5-15v / v% sodium N-lauroyl sarcosinate as a cell lysis and equilibration reagent; a reagent B comprising sodium acetate; and a reagent C comprising phenol, chloroform and isoamyl alcohol at a volume ratio of (120-130) : (19-29) : 1. Reagents B and C are used for mixing with a sample of the total DNA from the lysed cells and undergoing phase separation so as to obtain the aqueous phase of the mitochondrial DNA.

The invention relates to the discovery of the virus consisting of Opisthorhabdovirus (ORV), Opisthorphenuilivirus (OPLV), Opisthorsivirus (OSV),Clonorsivirus (CSV), Clonorhabdovirus (CRV), Clonorphenuilivirus (CPLV), Schistohaemavirus (ShV), Schistohaematogalivirus (ShTLV), Schistohaemendornavirus (ShMV) and Schistorhabovirus (ShRV) from the Class I carcinogen trematodes Schistosoma haematobium, Opisthorchis viverrini and Clonorchis sinensis and provide evidence of fluke-borne infection of parasitized vertebrate hosts.. The invention provides viruses, nucleic acids, proteins, peptides, and antibodies useful for diagnosis, treatment, and prevention of viral infection and associated diseases.

Pharmaceutical formulations are described for use in medicine, in particular for preventing, ameliorating, preventing progression of and / or treating arthritis, comprising artificial peptides characterized by a proline sequence prevalent in key matricellular proteins that partake in wound healing as well as in bone and cartilage formation and connective tissue maintenance in all vertebrates. The current invention relates to a pharmaceutical formulation in the form of a gel comprising a. an artificial peptide comprising the amino acid sequence of Pro-X-X-Pro-Y- Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-X- Pro-Y-Y-Y-Y-Y-Y-Pro-Y-Y-Y-Y-Y-Y-Pro-X-X-Pro-X- Pro-Y-Y-Y-Pro-Y-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Y-Pro-X-X- Pro-Y-Y-Pro-X-X-Pro-Y-Y- Pro-X-X-Pro-Y-Pro-Pro-X-Pro-Pro-X-X-X-X-X-X-X-X-Pro-X-X-Pro-X-X-X-X (SEQ ID NO 1 ) and / or an artificial peptide comprising or consisting of the amino acid sequence of Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y- Pro-X-X-Pro-Y-Y- Pro-Y-Pro-Pro-X-Pro-Pro (SEQ ID NO 2), wherein i) Pro is proline; ii) X is an amino acid selected from the group consisting of Ala, lie, Leu, Met, Phe, Trp and Vai; iii) Y is an amino acid selected from the group consisting of Asn, Cys, Gin, Ser, Thr and Tyr, b. cross-linked Hyaluronicfibres (HA-XL), and c. linear hyaluronic acid fibres (HA), for use in treating inflamed, degenerated and / or damaged joints.

The invention relates to the technical field of biology, in particular to a construction method of transgenic vertebrates with sex specific sterility and fertility simultaneously and application of the transgenic vertebrates in persistent population control. According to the construction method, a sex-specific sterile gene is taken as a target gene, and a transgenic technology is utilized to enable a targeted mutagenesis system to be continuously expressed and stably inherited in vertebrates, so that the sex-specific sterile gene function is inactivated, a sex-specific sterile phenotype and a fertile phenotype are generated at the same time, and then the sex-specific sterile phenotype and the fertile phenotype are applied to persistent population control. The invention creates a population inhibition method with stable inheritance (sustainable effect) and strong universality (especially applicable to vertebrates such as fish), so that the vertebrates can induce inheritable sex-specific sterility in a target population, thereby realizing continuous and specific population inhibition.

Provided is an approach which can express and function a G protein-coupled receptor (GPCR). The present invention provides a method for expressing a GPCR polypeptide, comprising expressing in a cell a GPCR polypeptide consisting of an amino acid sequence obtained by, in an amino acid sequence of a GPCR of interest (provided that an olfactory receptor is excluded), altering at least one amino acid residue different from that in a consensus amino acid sequence to an amino acid residue at a position corresponding thereto in the consensus amino acid sequence, wherein the consensus amino acid sequence is an amino acid sequence derived by alignment of the amino acid sequence of the GPCR of interest and amino acid sequences of GPCRs encoded by orthologs of the GPCR of interest in vertebrates.

The invention relates to blunt-snout bream terminal deoxynucleotidyl transferase and application thereof, and belongs to the technical field of gene engineering. The invention provides Branchiostoma belcheri terminal deoxynucleotidyl transferase (BbeTdT). The amino acid sequence of the Branchiostoma belcheri terminal deoxynucleotidyl transferase (BbeTdT) is shown as SEQ ID NO: 2 or SEQ ID NO: We find that terminal deoxynucleotidyl transferase (TdT) derived from Branchiostoma belcheri not only has terminal transferase activity under in vitro conditions, but also has nucleotide preference different from that of TdT of vertebrates. The BbeTdT has better selectivity aiming at a specific sequence or a terminal structure, and non-specific addition can be reduced in a practical application process, so that complementation with mammal TdT is formed, and the BbeTdT is suitable for industrial processes needing different preferences. In addition, the BbeTdT mutant is constructed, the activity of the terminal transferase of the BbeTdT mutant is higher, and the engineering transformation potential of the BbeTdT is further optimized.

The invention discloses a microbial agent for preventing and treating bemisia tabaci and application of the microbial agent. The microbial agent is bacillus subtilis MJ-4 fermentation liquor obtained by taking bacillus subtilis MJ-4 as a strain and performing seed activation and fermentation. According to the invention, the bacillus subtilis MJ-4 with insecticidal broad spectrum is used as a biocontrol bacterium for preventing and treating the harm of the bemisia tabaci, aiming at the problems in the existing prevention and treatment, the bemisia tabaci is prevented and treated to generate drug resistance, and the environment-friendly, non-toxic and harmless biological prevention and treatment are realized; the strain MJ-4 is environment-friendly, can be combined with bait, can well attract bemisia tabaci to eat, has a remarkable killing effect, has no adverse effect on vertebrates, and can be developed and utilized as a good biological control fungicide due to the fact that bacterial powder is easy to produce and low in cost.

Antimicrobial modified defensin or defensin-like peptides, modified C-terminal fragments of defensins or defensin-like peptides, and nucleic acids encoding them are disclosed. Compositions containing the defensin mutant peptides and methods of using them to control microbial infections in plants and vertebrates, and to control feed and food contamination are also disclosed.

Pharmaceutical and / or cosmetic formulations containing artificial peptides and their medical uses are described, the artificial peptides being characterized by proline sequences that are ubiquitous in key stromal cell proteins involved in wound healing, bone and cartilage formation, and the maintenance of connective tissue in all vertebrates. This invention relates to a pharmaceutical formulation in gel form, comprising a. a substance comprising Pro-X-X-Pro-Y-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Y-Y-Pro-Y-Y-Y-Pro-Y-Y-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Y-Pro-X-X-Pro-Y-Y-Y-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-X ... Artificial peptides comprising the amino acid sequence of NO:1) and / or artificial peptides comprising or composed of the amino acid sequence Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-Pro-X-Pro-Pro (SEQ ID NO:2), wherein i) Pro is proline; ii) X is an amino acid selected from Ala, Ile, Leu, Met, Phe, Trp and Val; iii) Y is an amino acid selected from Asn, Cys, Gln, Ser, Thr and Tyr; b. cross-linked hyaluronic acid fibers (HA-XL) and c. linear hyaluronic acid fibers (HA).

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

The present invention discloses self-assembled ferritin nanoantigen particles and influenza vaccines and preparation methods. The present invention fuses the extracellular domain of influenza virus hemagglutinin protein with the N-terminus of the subunit of self-assembled ferritin nanoparticles, and displays the influenza virus hemagglutinin protein on the surface of the self-assembled ferritin cage structure. The present invention performs mutation optimization on the influenza virus hemagglutinin protein to increase its soluble expression amount and expression efficiency, increase the immune efficacy and width of the vaccine, and increase the immunogenicity of the influenza virus hemagglutinin protein. The present invention utilizes Escherichia coli prokaryotic expression system, silkworm and AcMNPV-insect cell eukaryotic expression system to express and prepare recombinant protein vaccines respectively, or generates antigen-induced antibody production by gene presentation in vertebrate body tissues through recombinant baculovirus. The influenza vaccine of the present invention can induce broadly neutralizing anti-influenza antibodies, which can not only improve the immune efficacy but also expand the immune range, and has the potential of a universal vaccine with cross-immunity efficacy.

Pharmaceutical formulations are described and their uses in medicine comprising artificial peptides characterized by a proline sequence prevalent in key matricellular proteins that partake in wound healing as well as in bone and cartilage formation and connective tissue maintenance in all vertebrates. The current invention relates to a pharmaceutical formulation in the form of a gel comprising a. an artificial peptide comprising the amino acid sequence of Pro-X-X-Pro-Y-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-X- Pro-Y-Y-Y-Y-Y-Y-Pro-Y-Y-Y-Y-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Pro-Y-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Y-Pro-X-X- Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Pro-Pro-X-Pro-Pro-X-X-X-X-X-X-X-X-Pro-X-X-Pro-X-X-X-X (SEQ ID NO 1) and / or an artificial peptide comprising or consisting of the amino acid sequence of Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y- Pro-X-X-Pro-Y-Y- Pro-Y-Pro-Pro-X-Pro-Pro (SEQ ID NO 2), wherein i) Pro is proline; ii) X is an amino acid selected from the group consisting of Ala, Ile, Leu, Met, Phe, Trp and Val; iii) Y is an amino acid selected from the group consisting of Asn, Cys, Gln, Ser, Thr and Tyr, b. cross-linked Hyaluronicfibres (HA-XL), and / or c. non-crosslinked Hyaluronic fibres (HA), for use in treating inflamed, degenerated and / or damaged joints.

Pharmaceutical and / or cosmetic formulations are described and their uses in medicine comprising artificial peptides characterized by a proline sequence prevalent in key matricellular proteins that partake in wound healing as well as in bone and cartilage formation and connective tissue maintenance in all vertebrates. The current invention relates to a pharmaceutical formulation in the form of a gel comprising a. an artificial peptide comprising the amino acid sequence of Pro-X-X-Pro-Y-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Y-Y-Y-Pro-Y-Y-Y-Y-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Pro-Y-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Y-Pro-X-X- Pro-Y-Y-Pro-X-X-Pro-Y-Y- Pro-X-X-Pro-Y-Pro-Pro-X-Pro-Pro-X-X-X-X-X-X-X-X-Pro-X-X-Pro-X-X-X-X (SEQ ID NO 1 ) and / or an artificial peptide comprising or consisting of the amino acid sequence of Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y- Pro-X-X-Pro-Y-Y- Pro-Y-Pro-Pro-X-Pro-Pro (SEQ ID NO 2), wherein i) Pro is proline; ii) X is an amino acid selected from the group consisting of Ala, lie, Leu, Met, Phe, Trp and Vai; iii) Y is an amino acid selected from the group consisting of Asn, Cys, Gin, Ser, Thr and Tyr, b. cross-linked Hyaluronic fibres (HA-XL), and c. linear hyaluronic acid fibres (HA).

A biocompatible antimicrobial composition effective against microbial biofilms, including in vivo biofilms containing gram-positive bacteria, can be delivered to and used near the spinal column of vertebrates. Once introduced to an area colonized with a bacterial biofilm, particularly an intervertebral disc, the antimicrobial composition weakens the EPS / ECPS macromolecules of the biofilm, which makes the entire biofilm structure susceptible to being dislodged from the affected area or biosorbed. Additionally or alternatively, certain of the subcomponents of the solute component, as well as perhaps the organic liquid(s) of the solvent component, might lyse microbes, particularly gram-positive bacteria, previously protected by the EPS / ECPS macromolecules. Swelling of and around previously impacted intervertebral discs can be reduced or eliminated, often resulting in appreciable reductions in patient pain levels.

Pharmaceutical and / or cosmetic formulations are described and their uses in medicine comprising artificial peptides characterized by a proline sequence prevalent in key matricellular proteins that partake in wound healing as well as in bone and cartilage formation and connective tissue maintenance in all vertebrates. The current invention relates to a pharmaceutical formulation in the form of a gel comprising a. an artificial peptide comprising the amino acid sequence of Pro-X-X-Pro-Y-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Y-Y-Y-Pro-Y-Y-Y-Y-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Pro-Y-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Pro-Pro-X-Pro-Pro-X-X-X-X-X-X-X-X-Pro-X-X-Pro-X-X-X-X (SEQ ID NO 1) and / or an artificial peptide comprising or consisting of the amino acid sequence of Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y- Pro-X-X-Pro-Y-Y- Pro-Y-Pro-Pro-X-Pro-Pro (SEQ ID NO 2), wherein i) Pro is proline; ii) X is an amino acid selected from the group consisting of Ala, Ile, Leu, Met, Phe, Trp and Val; iii) Y is an amino acid selected from the group consisting of Asn, Cys, Gln, Ser, Thr and Tyr, b. cross-linked Hyaluronic fibres (HA-XL), and / or c. non-crosslinked Hyaluronic fibres (HA).